Chemokine migration assays fail for predictable reasons: a species-mismatched ligand, a freeze-thawed aliquot, or a dose outside the bell-shaped chemotaxis curve. This guide maps cell types to their chemokine-receptor pairs, walks through the four selection decisions that matter, and lists the assay parameters that determine whether your transwell results are interpretable.
Chemokine–Receptor Pairing Table
| Cell type | Key receptors | Primary chemokines |
|---|---|---|
| Monocytes / macrophages | CCR2, CCR5 | CCL2 (MCP-1), CCL5 (RANTES) |
| Neutrophils | CXCR1, CXCR2 | CXCL8 (IL-8), CXCL1 (GRO-α) |
| Effector T cells (Th1) | CXCR3, CCR5 | CXCL10 (IP-10), CCL5 |
| Tregs | CCR4, CCR8 | CCL22, CCL17, CCL1 |
| NK cells | CXCR4, CCR2 | CXCL12 (SDF-1), CCL2 |
| B cells | CXCR4, CXCR5 | CXCL12, CXCL13 |
| Dendritic cells | CCR7 | CCL19, CCL21 |
| Eosinophils | CCR3 | CCL11 (Eotaxin) |
Before ordering a chemokine, confirm your target cells express the matching receptor by flow cytometry. A chemokine with no receptor on your cells will not migrate them — regardless of quality or concentration.
1. Species Matching: The Most Common Mistake
Chemokine-receptor interactions are species-restricted. Mouse CCL2 does not reliably activate human CCR2, and human CXCL12 shows reduced potency on mouse CXCR4. Rule of thumb: human cells → human chemokines; mouse in vivo models → mouse chemokines. BioCrest Sci provides 180+ recombinant chemokines from human, mouse, rat, and 50+ additional species.
2. Purity and Endotoxin: What Actually Affects Migration
- Purity: greater than 90% by SDS-PAGE is the baseline. Contaminating cytokines in chemokine preps are rare but catastrophic — a 1% contamination with a potent chemoattractant can dominate the readout
- Endotoxin: target <1 EU/μg for primary cell assays. LPS activates monocytes and alters chemokine receptor expression within hours, confounding chemotaxis
- Bioactivity: request ED50 values from a validated chemotaxis assay rather than assuming activity from purity data
3. Match the Format to the Assay
| Assay format | Recommended protein format |
|---|---|
| Transwell (Boyden chamber) | Active chemokine, tag-free preferred, verified ED50 |
| Microfluidic devices | Tag-free; small tags acceptable; carrier-free required |
| SPR / BLI receptor binding | His- or Avi-tagged for oriented immobilization |
| In vivo studies | Carrier-free, endotoxin-tested |
4. Assay Parameters That Determine Success
- Concentration range: chemotaxis is dose-dependent and bell-shaped. Titrate from 0.1 to 100 nM in log steps — migration peaks at intermediate concentrations and falls at both extremes (receptor desensitization at high dose)
- Controls: always include a medium-only negative control and, if possible, a known chemoattractant positive control (e.g., 10% FBS or CXCL12 for lymphocytes)
- Aliquot handling: chemokines lose activity after 2–3 freeze-thaw cycles. Aliquot at first reconstitution and use fresh aliquots per experiment
- Migration time: optimize the endpoint (typically 2–4 h for lymphocytes, 1–2 h for neutrophils); overly long assays mask chemotaxis with random migration
Common Pitfalls and Fixes
| Observation | Likely cause | Fix |
|---|---|---|
| No migration at any dose | Species mismatch or receptor not expressed | Verify receptor by flow cytometry; switch species |
| Migration only at very high dose | Lost bioactivity (freeze-thaw) or endotoxin noise | Fresh aliquot; check endotoxin level |
| High background in negative control | Medium chemotaxis (FBS content) or over-long assay | Use chemotaxis medium; shorten assay |
FAQ
Can I use one chemokine for multiple cell types?
Only if the cell types share the receptor. CXCL12 (via CXCR4) works for lymphocytes, NK cells, and hematopoietic progenitors — but verify receptor expression for each population.
How do I store reconstituted chemokines?
Aliquot at 0.1–1.0 mg/mL, store at -80°C, and use within one week at 4°C. Avoid repeat freeze-thaw cycles.
Do I need carrier-free chemokines for transwell assays?
Yes for quantitative work — carrier proteins (BSA) contribute to background migration and interfere with dose-response curves.
References
- Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity. 2012;36(5):705-16.
- Justus CR, Leffler N, Ruiz-Echevarria M, Yang LV. In vitro cell migration and invasion assays. J Vis Exp. 2014;(88):51046.
By BioCrest Sci Research Team. Last reviewed August 2026.
Browse the Chemokines resource hub or all 183 recombinant chemokines. Contact sales@biocrestsci.com for assay-specific recommendations.